Literature DB >> 22827224

mRNA as a versatile tool for exogenous protein expression.

Andreas N Kuhn1, Tim Beiβert, Petra Simon, Britta Vallazza, Janina Buck, Brian P Davies, Ozlem Tureci, Ugur Sahin.   

Abstract

Several viral and non-viral vectors have been developed for exogenous protein expression in specific cells. Conventionally, this purpose is achieved through the use of recombinant DNA. But mainly due to the risks associated with permanent genetic alteration of cells, safety and ethical concerns have been raised for the use of DNA-based vectors in human clinical therapy. In the last years, synthetic messenger RNA has emerged as powerful tool to deliver genetic information. RNA vectors exhibit several advantages compared to DNA and are particularly interesting for applications that require transient gene expression. RNA stability and translation efficiency can be increased by cis-acting structural elements in the RNA such as the 5'-cap, the poly(A)-tail, untranslated regions and the sequence of the coding region. Here we review recent developments in the optimization of messenger RNA as vector for modulation of protein expression emphasizing on stability, transfection and immunogenicity. In addition, we summarize current pre-clinical and clinical studies using RNA-based vectors for immunotherapy, T cell, stem cell as well as gene therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827224     DOI: 10.2174/156652312802762536

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  16 in total

Review 1.  Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases.

Authors:  Rutao Liu; Jing Liu; Xiaofei Ji; Yang Liu
Journal:  Metab Brain Dis       Date:  2013-12       Impact factor: 3.584

Review 2.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

3.  Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo.

Authors:  Yitian Xu; Lu Huang; Jonathan L Kirschman; Daryll A Vanover; Pooja M Tiwari; Philip J Santangelo; Xiling Shen; David G Russell
Journal:  J Immunol       Date:  2018-12-12       Impact factor: 5.422

4.  Fibroblast Growth Requires CT10 Regulator of Kinase (Crk) and Crk-like (CrkL).

Authors:  Taeju Park; Mateusz Koptyra; Tom Curran
Journal:  J Biol Chem       Date:  2016-11-02       Impact factor: 5.157

Review 5.  mRNA Vaccines: Why Is the Biology of Retroposition Ignored?

Authors:  Tomislav Domazet-Lošo
Journal:  Genes (Basel)       Date:  2022-04-20       Impact factor: 4.141

6.  Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential.

Authors:  Gábor Boros; Edit Miko; Hiromi Muramatsu; Drew Weissman; Eszter Emri; Dávid Rózsa; Georgina Nagy; Attila Juhász; István Juhász; Gijsbertus van der Horst; Irén Horkay; Éva Remenyik; Katalin Karikó; Gabriella Emri
Journal:  J Photochem Photobiol B       Date:  2013-10-11       Impact factor: 6.252

7.  mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease.

Authors:  Jingsong Cao; Minjung Choi; Eleonora Guadagnin; Maud Soty; Marine Silva; Vincent Verzieux; Edward Weisser; Arianna Markel; Jenny Zhuo; Shi Liang; Ling Yin; Andrea Frassetto; Anne-Renee Graham; Kristine Burke; Tatiana Ketova; Cosmin Mihai; Zach Zalinger; Becca Levy; Gilles Besin; Meredith Wolfrom; Barbara Tran; Christopher Tunkey; Erik Owen; Joe Sarkis; Athanasios Dousis; Vladimir Presnyak; Christopher Pepin; Wei Zheng; Lei Ci; Marjie Hard; Edward Miracco; Lisa Rice; Vi Nguyen; Mike Zimmer; Uma Rajarajacholan; Patrick F Finn; Gilles Mithieux; Fabienne Rajas; Paolo G V Martini; Paloma H Giangrande
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

8.  Inhibition of Xenograft tumor growth by gold nanoparticle-DNA oligonucleotide conjugates-assisted delivery of BAX mRNA.

Authors:  Ji-Hyun Yeom; Sang-Mi Ryou; Miae Won; Mira Park; Jeehyeon Bae; Kangseok Lee
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 9.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Authors:  Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

10.  Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies.

Authors:  Justin S Antony; Alexander Dewerth; Ashiqul Haque; Rupert Handgretinger; Michael S D Kormann
Journal:  Mol Cell Pediatr       Date:  2015-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.